German pharmaceutical company specializing in pain therapeutics, contributing drug discovery, clinical expertise, and digital health capabilities to EU pain research consortia.
Grünenthal is a German pharmaceutical company headquartered in Aachen, focused on pain therapy and pain management research. In H2020, they contribute industry expertise to large public-private consortia developing better pain treatments, patient-reported outcome measures, and digital health tools. Their involvement spans from basic drug discovery (neuron-glia pain models, high-throughput screening) to clinical validation of digital mobility assessments and patient empowerment in medication management. As an EFPIA member in IMI projects, they bring pharmaceutical R&D infrastructure, clinical trial capabilities, and regulatory know-how to academic-industry partnerships.
Core focus across BonePain (bone pain training network), NGN-PET (neuron-glia pain models for drug discovery), IMI-PainCare (acute/chronic pain care improvement), demonstrating deep commitment to pain science.
NGN-PET developed pain-specific drug discovery platforms, ESCulab provided access to European screening compound libraries, and BonePain trained next-generation pain researchers.
MOBILISE-D connects digital mobility biomarkers to clinical outcomes across COPD, Parkinson's, and MS populations; Gravitate-Health builds digital tools for medication self-management.
PARADIGM advanced patient involvement in medicines development processes; Gravitate-Health focuses on health information standards and adherence improvement.
IMI-PainCare incorporates deep phenotyping, biomarker discovery, and patient stratification for conditions like endometriosis and bladder pain syndrome.
Grünenthal's early H2020 participation (2015–2018) centered on fundamental pain biology — training networks for bone pain research and computational models of neuron-glia interactions for drug discovery. From 2018 onward, their focus broadened significantly into digital health outcomes (MOBILISE-D), patient-centered care (IMI-PainCare, Gravitate-Health), and regulatory-grade digital endpoints. This shift mirrors the wider pharmaceutical industry's move from molecule-centric R&D toward real-world evidence, digital biomarkers, and patient empowerment in treatment decisions.
Grünenthal is moving toward digital health endpoints, real-world evidence generation, and patient self-management tools — expect future interest in decentralized clinical trials and AI-driven pain diagnostics.
Grünenthal operates exclusively as a consortium participant, never as coordinator — typical for large pharmaceutical companies in IMI and RIA projects where academic partners usually lead. With 154 unique partners across 20 countries, they engage in very large consortia (averaging 20+ partners per project), reflecting the IMI model of broad public-private partnerships. Their role is that of an industry anchor: contributing proprietary data, compound libraries, clinical infrastructure, and regulatory expertise while benefiting from academic innovation.
Extensive European network spanning 154 unique partners across 20 countries, heavily concentrated in Western Europe's pharmaceutical and academic research ecosystem. Their IMI participation connects them to major pharma peers, leading university hospitals, and regulatory bodies across the EU.
Grünenthal brings a rare combination of deep pain specialization and pharmaceutical-scale R&D capability to EU consortia. Unlike generalist pharma participants, their entire H2020 portfolio revolves around pain — from molecular mechanisms to digital patient outcomes — making them the go-to industry partner for any pain-related research initiative. Their participation in both IMI projects and standard RIA grants shows willingness to engage across different funding instruments and partnership models.
